A Cohort Study Evaluating The Efficacy Of Epidiolex® Against Kriya® Hops CBD

Intro: Dr. Luisa Rocha, conducted an epilepsy study that showed Kriya® Hops CBD completely eradicated Pentylenetetrazol generalized seizures (stage IV and V) in rats. This study extends it to humans and the ability of Epidiolex® and Kriya® Hops CBD to prevent Tonic-Clonic, Tonic, Clonic, Myoclinic, Absence and Atonic seizures.

Method: An Epilepsy Assessment of Functioning (EAF) scale was developed. The scores range from the sickest to the healthiest patient with definitions of severity by scores. 100 means the patient is seizure free. 80 means the patient has seizures while sleeping and is functioning normally. There were a total of 1247 people in the study. Six types of seizures were studied.

Results: Welch’s t was used to make our corrected group comparisons. It found a significant difference in monthly seizure rate between the control group and the treatment group, t(23.386) = 24.5, p < .001, d = 7.58. It appears that supplying epilepsy patients with treatment significantly reduced their seizures, and dramatically improved their quality of health. There was a clear main effect of the Kriya® Hops CBD treatment, F(3, 34) = 36.72, p < .001, η2 = .03 and an interaction effect of group and Kriya® Hops CBD treatment type F(3, 34) = 40.27, p < .001 η2 = .04. The general benefit of having Kriya® Hops CBD treatment appears to heavily outweigh any differences between epilepsy types.

Discussion: We confirm the results of Dr. Luisa Rocha in humans. Kriya® Hops CBD increased EAF scores twice as fast as Epidiolex®, almost doubled the EAF score when compared to Epidiolex® (96% increase) and did not have the ten fold spike in ALT liver enzyme that Epidiolex® had.